abstract
Diabetes mellitus is one of the most common pregnancy complications. In the United States, gestational diabetes mellitus affects ∼7% of pregnancies, and preexisting diabetes complicates ∼1.3% of pregnancies. 1, 2 Diabetic pregnancies, particularly those with poor glycemic control and more advanced diabetes, are at high risk of both indicated and spontaneous preterm delivery. [3] [4] [5] [6] Few studies have examined the resulting complications and neurodevelopmental outcomes among extremely preterm infants born to diabetic mothers, and none has examined the impact of glycemic control mode on infant outcomes. [7] [8] [9] With the increasing incidence of both gestational and pregestational diabetes 10 and the high incidence of preterm birth associated with diabetes, it is imperative to examine outcomes in this high-risk group of infants.
We used data from a high-risk infant registry maintained by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (NRN) to examine mortality, morbidity, and neurodevelopmental outcomes among extremely preterm infants whose mothers used insulin before pregnancy, those whose mothers first began insulin use during pregnancy, and those whose mothers had no insulin-dependent diabetes mellitus (IDDM).
METHODS
Infants born at 1 of the NRN centers from January 1, 2006 , through December 31, 2011 , with gestational age (GA) of 22 to 28 weeks and enrolled in the registry were studied. In 2006 and 2007, all very low birth weight (VLBW) infants (401-1500 g) born at or admitted to a study center within 14 days of birth were included in the registry.
Beginning 2008, eligibility criteria changed to include inborn infants with GA 22 to 28 weeks or birth weight 401 to 1000 g. To maintain consistency over the study period, we restricted our cohort to inborn infants with GA of 22 to 28 weeks. The institutional review board at each center approved participation in the registry.
Trained research nurses prospectively collected maternal demographic, pregnancy, and delivery information and infant data from birth to discharge, transfer, death, or 120 days. Maternal IDDM was recorded if the mother required insulin for diabetes control before or during pregnancy. Except for insulin requirement, data on diabetes onset and type and milder diabetes forms managed by diet or oral hypoglycemic agents were not recorded. Maternal hypertension before or during pregnancy was recorded if noted in the mother's chart. Preeclampsia and eclampsia were not collected. Infant characteristics, delivery room interventions, and final status were recorded for all infants.
In-Hospital Outcomes
Morbidities diagnosed in-hospital were recorded for infants surviving >12 hours. These included respiratory distress syndrome (RDS); patent ductus arteriosus (PDA); modified Bell's stage ≥IIA necrotizing enterocolitis (NEC) 11, 12 ; early-onset sepsis (EOS; ≤72 h of age) and lateonset sepsis (LOS; >72 h), defined by a positive blood culture and intent to treat with antibiotics for ≥5 days; severe intraventricular hemorrhage (IVH) grade 3 or 4 13 ; cystic periventricular leukomalacia (PVL); retinopathy of prematurity (ROP); and bronchopulmonary dysplasia (BPD). Standard scores (z scores) and percentiles for infant weight, length, and head circumference measured at birth and at 36 weeks' postmenstrual age (PMA) were calculated by using Olsen norms, 14 available for males and females born at 23 to 41 weeks' GA. Ponderal index was calculated at birth and 36 weeks' PMA as follows: [weight g / (length cm) 3 ] × 100. Microcephaly was defined as head circumference z score < −2.
Follow-up Outcomes
Surviving infants were eligible for assessment at 18 to 22 months' corrected age (CA) if they weighed 401 to 1000 g at birth (those 18 months' CA before January 1, 2008) , were born at ≤26 weeks' GA, or were enrolled in an NRN study with follow-up (those 18 months' CA on or after January 1, 2008) . The visit included a neurologic examination and a developmental assessment by using the Bayley Scales of Infant Development III, 15 both by certified examiners, as well as caregiver interview and measurement of infant weight, length, and head circumference. Neurodevelopmental impairment (NDI; 2006 definition) was defined as ≥1 of the following: bilateral blindness, hearing impairment (permanent hearing loss), moderate to severe cerebral palsy, gross motor function level ≥2, or Bayley III cognitive composite score <70. Beginning January 1, 2010, the Bayley III motor score was collected and a motor composite score <70 was added to the NDI definition. Growth at follow-up was assessed by weight, length, and head circumference-for-age z scores determined by World Health Organization Child Health Standards 16, 17 and by the ponderal index.
Data Analysis
Characteristics and outcomes were compared between infants in the following groups defined by maternal IDDM status and timing of insulin use: insulin use before pregnancy (IBP), insulin use started during pregnancy (IDP), and no IDDM. Fisher's exact, χ 2 , or t test was used to determine statistical significance for unadjusted comparisons. Poisson regression models with robust variance estimators 18 were used to assess risk of mortality and other binary outcomes and included an insulin use and timing indicator (IBP, IDP, no IDDM) to allow for pairwise contrasts adjusting for study center, infant gender, GA, antenatal steroid use, maternal age, and maternal race/ethnicity. Maternal education was added to models assessing 18-to 22-month outcomes. Adjusted relative risks (RRs), 95% confidence intervals (CIs), and P values by the Score or Wald χ 2 test from these models are reported. Linear regression models compared mean growth measures in the insulin groups adjusting for the covariates noted earlier, with P values for pairwise contrasts by the t test. Changes in z scores for weight, height, and head circumference at birth, 36 weeks', and 18 to 22 months' CA were evaluated in the subset of infants with measurements at 18-to 22-month follow-up in a longitudinal model using generalized estimating equations with an exchangeable correlation structure.
The primary binary outcomes were conditioned on the infant surviving to the risk period. Composite outcomes of morbidity or death were also examined and defined as "yes" if an infant had the outcome or died before the outcome was evaluated (for RDS, PDA, NEC, and EOS, death within 12 hours; for LOS, death within 3 days; for IVH and PVL, death before sonography; for ROP, death within 28 days; for BPD, death before 36 weeks' PMA) and "no" if the infant survived until evaluation and did not have the morbidity. Composite death or 18-to 22-month outcomes were defined similarly, with deaths before 18 to 22 months included. Supplemental Tables 5 and 7 show results of comparisons on composite outcomes.
As a sensitivity analysis, all models assessing mortality, in-hospital morbidity, growth at 36 weeks' PMA, neurodevelopmental outcomes at 18 to 22 months' CA, and growth between birth and 18 to 22 months were rerun including additional adjustment for chronic maternal hypertension. Inference related to comparisons between insulin groups was unchanged, and results after adjusting for chronic maternal hypertension are not shown. P values were not adjusted for multiple comparisons. Analyses were performed by using SAS version 9.3 (SAS Institute, Cary, NC). Table 5 ). Among infants still hospitalized at 28 days, ROP was diagnosed in 57% of infants with maternal IBP and 49% with maternal IDP (RR = 1.23, 95% CI: 1.04-1.45). RRs were similar when deaths within 28 days were added to this outcome. There were no significant differences among the 3 groups in the risk of PDA, EOS, IVH, PVL, or BPD (Table  2) or the composite risk of each morbidity or death (Supplemental Table 5 80 (26) 52 (27) 2641 (26) [30] [31] [32] [33] [34] 96 (31) 58 (30) 2265 (22) [35] [36] [37] [38] [39] 56 (18) 33 (17) 1115 (11) ≥40 14 (4) 23 (12) 315 ( (25) 1826 (26) High school degree 63 (33) 32 (23) 2022 (29) Partial college 55 (29) 31 (22) 1508 (21 (32) 79 (41) 4077 (40) Hispanic 50 (16) 33 (17) 1824 (18) Other 13 (4) 24 (12) 491 (5 (10) 26 (14) 917 (9) by guest on September 13, 2017 Downloaded from with IDP (-0.99 [1.07] ) and infants without maternal IDDM (-1.07 [1.01] ) and a larger proportion had microcephaly compared with infants without maternal IDDM (25% vs 18%, P = .003; Table 3 ). There were no significant differences in weight and length.
RESULTS

Study Population
Growth at 18 to 22 Months' Follow-up and Changes From Birth to 18 to 22 Months
Among the 4292 children surviving to 18 to 22 months' CA and eligible for follow-up, 3883 (90%) completed the follow-up visit between September 2007 and April 2014 with similar compliance with and without maternal IDDM (93% vs 90%). There were no differences in GA or birth weight among infants in the 3 groups who attended follow-up (Supplemental Table 6 ). Mothers with IBP showed higher rates of chronic hypertension than mothers in the other 2 groups. The rate of birth defects was higher among infants of mothers with IBP (7%) compared with those with IDP (0%) and those without IDDM (2%).
At 18 to 22 months, mean weight, length, and head circumference z scores were significantly lower for infants of mothers with IBP compared with infants of mothers without IDDM. Although also lower compared with z scores for infants of mothers with IDP, differences did not reach statistical significance (Table 3 ).
In the subset of children with at least 1 of weight, length, or head circumference measured at 18 to 22 months (n = 3877), z score trends were examined between birth, 36 weeks' PMA, and 18 to 22 months. Differences between the groups were consistent over (7) 11 (6) 852 (8) Epinephrine 18 (6) 8 (4) 475 (5 15 (5) 4 (2) 373 (4) CPAP, continuous positive airway pressure; HT, hypertension. a Information was missing in the groups shown for maternal age, 1 infant; maternal education, 3389 infants; maternal race/ethnicity, 33 infants; prenatal visits, 5 infants; maternal HT, 2 infants; maternal HT before or not before pregnancy, 106 infants; maternal antenatal steroids, 30 infants; birth weight, 15 infants; length at birth, 857 infants; head circumference at birth, 1009 infants; ponderal index, 1053 infants; Apgar at 1 min, 92 infants; Apgar at 5 min, 87 infants; mode of delivery, 5 infants; delivery room oxygen, CPAP, intubation, chest compression, 7 infants; delivery room bagging and mask, 9 infants; delivery room epinephrine, 8 infants; ventilator support, 4 infants; surfactant therapy, 2 infants. b z scores and percentiles from Olsen. 14 Small for GA was defi ned as weight, length, or head circumference <10th percentile and large for GA >90th percentile. The Olsen measures are available for male and female infants born at GA 23-41 wk. Therefore, 462 infants born at 22 wk GA could not be included. In the group of 10 290 infants born at GA 23-28 wk, birth weight was missing/excluded for 13 infants, length for 597 infants, and head circumference for 672. c After adjustment for study center, GA, male gender, antenatal steroid use, maternal age, and maternal race/ethnicity, results for comparisons of z score means were similar to unadjusted results with 1 exception. The mean z score for head circumference was not signifi cantly different for infants whose mothers used insulin before pregnancy versus those whose mothers started insulin during pregnancy, adjusted P = .054 (unadjusted P = .017). d Ventilator support was defi ned as use of high frequency or conventional ventilation for infants who survived >12 h. For infants born in 2006-2010 who died ≤12 h, all forms of support with a ventilator after initial resuscitation were included. Beginning in 2011, respiratory support recorded for infants who died ≤12 h was defi ned as any ventilator pressure support and/or supplemental oxygen delivery by any method. In the subset of 9585 infants who survived >12 h, the percent who received mechanical ventilation did not vary signifi cantly between groups (IBP: 88%, IDP: 83%, no IDDM: 88%; P = .17). * P ≤ .05, ** P ≤ .001 by t test (means for maternal age, GA, birth weight, length, head circumference, ponderal index, z score), the row mean score χ 2 test with modifi ed ridit scores specifi ed (categorical maternal age, GA, birth weight, head circumference z score, and percentiles), the general association χ 2 test, or Fisher's exact test. Pairwise comparisons were performed between infants with maternal IBP versus infants with maternal IDP and infants with no maternal IDDM, and between infants with maternal IDP versus infants with no maternal IDDM. For each signifi cant result, the comparison group is indicated. *** P ≤ .01,
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by guest on September 13, 2017 Downloaded from time (nonsignificant interaction between insulin group and time for weight, P = .51; length, P = .29; head circumference, P = .48). Mean head circumference z scores were significantly lower at birth for infants with maternal IBP than for infants without maternal IDDM and remained lower through 18 to 22 months (P = .004), but comparisons with infants whose mothers had IDP were not statistically significant (Fig  1) . Mean z scores for weight and length did not differ significantly among the 3 groups over time in this subset (P = .53 and P = .18, respectively). Results were nearly identical when analyses were repeated by using the subset of infants with measures at all 3 time points. Excluding infants with birth defects did not change the results.
Mortality and Neurodevelopmental Outcomes of Children at 18 to 22 Months' CA
For survivors seen at follow-up, NDI risk was not significantly increased for children of mothers with IBP or IDP compared with those without maternal IDDM (Table 4) , nor was the risk of the combined death or NDI outcome (Supplemental Table 7 ). Similarly, there were no significant differences in the individual components of NDI among the 3 groups (Table 4) .
DISCUSSION
In this large cohort of extremely preterm infants, infants whose 6 f Presence of IVH and/or PVL was determined for infants with nonmissing IVH and PVL outcomes, except that a diagnosis of either condition was suffi cient to set the outcome. g ROP was defi ned for infants still hospitalized at 28 d who had a ROP examination. By 28 d, 2331 infants had died, 5 had been discharged, and status was unknown for 10. Of the 8406 infants still in the hospital, 7959 (94.7%) had a ROP examination. Among those who had an examination, ROP was missing for 1 infant. h BPD was defi ned for infants born <36 wk GA as the need for supplemental oxygen use at 36 wk PMA. For infants discharged or transferred before 36 wk PMA, BPD was defi ned based on oxygen use at 36 wk if known or oxygen use at the time of discharge or transfer. BPD could not be evaluated for 87 (1%) of the 8121 infants alive at 36 wk PMA. Of the 8034 infants evaluated, 82% were still in the hospital at 36 wk PMA, 12% had been discharged from the hospital, and 5% had been transferred to another hospital.
by guest on September 13, 2017 Downloaded from mothers used insulin before pregnancy had significantly lower mean z scores for length and head circumference at birth compared with infants whose mothers started insulin during pregnancy and those whose mothers had no IDDM. While hospitalized, infants with maternal IBP were at higher risk of NEC and LOS compared with those born to mothers without IDDM, and those still hospitalized at 36 weeks' PMA had lower average head circumference z scores than either infants of mothers with IDP or infants without maternal IDDM. Among infants surviving and evaluated at 18 to 22 months, average head circumference z scores were significantly lower at birth, 36 weeks' PMA, and 18 to 22 months' CA for infants of mothers with IBP compared with infants of mothers without IDDM. Importantly, however, no differences in neurodevelopmental outcomes at 18 to 22 months were observed between the groups. (23) 14 (22) 638 (17) Greater than or equal to -1 73 (66) 46 (71) 2722 (75) a Measurements taken between 35 and 37 wk PMA were included. z scores and percentiles based on Olsen. 14 b z scores were determined based on the World Health Organization's Child Health Standards. * P ≤ .05, ** P ≤ .001 by t test from linear regression models (means) or by Wald χ 2 from modifi ed Poisson regression models (categorical outcomes) with adjustment for study center, GA (categorical), male gender, antenatal steroid use, maternal race/ethnicity (black, white, Hispanic, other), and maternal age. Models fi t to follow-up outcomes also included maternal education (less than high school degree, high school degree, partial college or more, missing). For categorical head circumference z score, tests were conducted for the binary outcome less than -2 versus Greater than or equal to -2, and study center was not included in the model because of small numbers. Pairwise comparisons were performed between infants with maternal IBP versus infants with maternal IDP and infants with no maternal IDDM and between infants with maternal IDP versus infants with no maternal IDDM. For each signifi cant result, the comparison group is indicated. *** P ≤ .01,
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FIGURE 1
Unadjusted mean growth measure z scores for age and gender at birth, 36 weeks' PMA, and 18 to 22 months' CA compared between infants with maternal IBP, IDP, and no IDDM in the subset of 3877 infants with at least 1 of weight, length, or head circumference measured at the 18-to 22-month visit. 48 (0.68-3.19) CP, cerebral palsy; CS, composite score. a RRs and CIs from modifi ed Poisson regression models fi t to each outcome that in addition to the maternal insulin timing indicator (IBP, IDP, no IDDM) included study center, GA (categorical), male gender, antenatal steroid use, maternal race/ethnicity (white, black, Hispanic, other), maternal age, and maternal education (less than high school degree, high school degree, partial college or more, missing). Study center was not included in the models fi t to blindness or hearing impairment due to small numbers. None of the infants whose mothers started IDP had NDI in the subset seen at follow-up before 2010, and none had hearing impairment; RRs involving this group were not estimated for these outcomes. 19 At birth, the proportion of infants small for GA on weight, length, and head circumference was largest among infants with maternal IBP. Of the 3 anthropometric measurements among infants of women with IBP, head circumference seems to be the most affected.
A study examining microcephaly incidence, defined as head circumference z score ≤−1.88, among liveborn infants (mean GA = 37 weeks) of women with IBP reported that the observed microcephaly incidence was less than expected and attributed this to the tendency of infants of diabetic mothers toward macrosomia and better glycemic control as measured by HbA1c. 20 In our study, microcephaly (z score ≤−2) at birth (7% vs 4%) and at 36 weeks (25% vs 18%) was significantly higher among infants of mothers with IBP compared with infants of mothers without IDDM. At 18 to 22 months' CA, however, microcephaly was not significantly increased among surviving infants of mothers with IBP compared with the other groups (11% vs 8%, respectively). The clinical significance of a smaller head circumference is debatable. Brain volume is a determinant of head size; however, microcephaly at 2 years, but not at birth, is predictive of severe motor and cognitive impairments. 21, 22 Both poor glycemic control and hypertension have previously been associated with preterm delivery among women with type 1 diabetes. [23] [24] [25] [26] Nearly 60% of the women with IBP had hypertension, a majority of whom had chronic hypertension. The increased malformations in this group in the subset of infants with follow-up data may be reflective of poor glycemic control. 27 One of our main study findings is that infants of mothers with IBP did not have a significantly increased rate of neurodevelopmental delays. Neurodevelopmental delays have been reported at increased rates among infants of diabetic mothers. 28, 29 Potential mechanisms that have been postulated relate to in utero hypoxia, brain iron deficiency, or hypoglycemia at birth. 28, 30, 31 Whether these same mechanisms are implicated in the smaller head circumference among infants of diabetic mothers with IBP is unknown.
To our knowledge, only 3 studies have examined the impact of maternal diabetes on morbidity and mortality of VLBW infants. [7] [8] [9] One study in Israel combined VLBW infants of mothers with gestational (n = 825) and pregestational diabetes (n = 120) into 1 group after finding no differences in demographic and delivery characteristics and reported no increased risks in hospital mortality or morbidities compared with VLBW infants of nondiabetic mothers (n = 12 209). 7 Another study in Latin America with no information on diabetes type examined in-hospital morbidities between VLBW infants of mothers with any type of diabetes (n = 304) and VLBW infants of mothers without diabetes (n = 10 563). The authors reported increased risk only for NEC (RR = 1.65, 95% CI: 1.21-2.27). 8 A third descriptive study of 43 VLBW infants of diabetic women (gestational and pregestational) showed no differences in hospital morbidities or neurodevelopmental outcomes at 18 months compared with controls. 9 None of these studies examined glycemic control method. Additionally, given the different database eligibility criteria, the mean GA in these studies was ∼29 weeks, considerably higher than 26 weeks in our study population.
The increased NEC risk in our study (RR = 1.55, 95% CI: 1.17-2.05) for infants of mothers with IBP compared with infants of mothers without IDDM and in the Latin American study might be due to higher polycythemia rates among these infants. Maternal hyperglycemia causes chronic fetal hyperglycemia and hyperinsulinemia, both of which increase fetal metabolic rate and oxygen requirements. 30 As the placenta is incapable of upregulating oxygen delivery to meet this higher demand, chronic fetal hypoxia ensues resulting in increased erythropoietin levels and subsequent polycythemia. 32, 33 Polycythemia has been previously shown to be a risk factor for NEC, although more commonly among term infants. [34] [35] [36] [37] [38] In addition to the potential role of diabetes in NEC, other maternal risk factors that reduce fetal gut blood flow, such as hypertensive disorders, have also been associated with NEC among VLBW infants. 39 In our study, maternal hypertension among mothers with IBP was 2.5 times higher than among mothers without IDDM (59% vs 23%). However, the RR of NEC for infants with maternal IBP compared with infants without maternal IDDM was unchanged after adjusting for maternal chronic hypertension, indicating that chronic hypertension does not account for all of this association. The NRN previously reported a 2.7-fold higher LOS risk in VLBW infants with NEC. 40 The increased risk of NEC may have contributed to the increased risk of LOS in this study for infants of mothers with IBP compared with infants of mothers without IDDM (RR = 1.26, 95% CI: 1.07-1.48).
Using a large prospective database of extremely preterm infants, we examined several important outcomes including neurodevelopmental outcomes with a high follow-up rate. We also had data on glycemic control method, which was lacking in previous studies. However, we had no data on diabetes onset and type, diabetes duration, insulin type and dosage, level of glycemic control, usage of antihypertensive medications, or the prevalence of diabetic nephropathy and microalbuminuria. We also had no data on when insulin use started during pregnancy or on the presence of diabetes controlled by diet or oral hypoglycemic agents.
CONCLUSIONS
We found that extremely preterm infants of diabetic mothers with IBP have smaller average head circumference and are at higher risk of NEC and LOS but are not at higher risk of adverse neurodevelopmental outcomes at 18 to 22 months' CA compared with infants born to women without IDDM. Additional study to elucidate factors contributing to the increased risk of NEC and LOS may improve clinical care of extremely preterm infants born to diabetic mothers with IBP.
ACKNOWLEDGMENTS
Data collected at participating sites of the NICHD NRN were transmitted to RTI International, the data coordinating center (DCC) for the network, which stored, managed, and analyzed the data for this study. On behalf of the NRN, Ms Nellie Hansen (DCC Statistician) and Dr Abhik Das (DCC Principal Investigator) had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis.
We are indebted to our medical and nursing colleagues and the infants and their parents who agreed to take part in this study. The following investigators, in addition to those listed as authors, participated in this study:
NRN Steering Committee Chair: Michael S. Caplan, MD, University of Chicago, Pritzker School of Medicine.
